Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism

ABSTRACT With 29 individual antiretroviral drugs available from six classes that are approved for the treatment of HIV-1 infection, a combination of different phenotypic and genotypic tests is currently needed to monitor HIV-infected individuals. In this study, we developed a novel HIV-1 genotypic assay based on deep sequencing (DeepGen HIV) to simultaneously assess HIV-1 susceptibilities to all drugs targeting the three viral enzymes and to predict HIV-1 coreceptor tropism. Patient-derived gag-p2/NCp7/p1/p6/pol-PR/RT/IN- and env-C2V3 PCR products were sequenced using the Ion Torrent Personal Genome Machine. Reads spanning the 3′ end of the Gag, protease (PR), reverse transcriptase (RT), integrase (IN), and V3 regions were extracted, truncated, translated, and assembled for genotype and HIV-1 coreceptor tropism determination. DeepGen HIV consistently detected both minority drug-resistant viruses and non-R5 HIV-1 variants from clinical specimens with viral loads of ≥1,000 copies/ml and from B and non-B subtypes. Additional mutations associated with resistance to PR, RT, and IN inhibitors, previously undetected by standard (Sanger) population sequencing, were reliably identified at frequencies as low as 1%. DeepGen HIV results correlated with phenotypic (original Trofile, 92%; enhanced-sensitivity Trofile assay [ESTA], 80%; TROCAI, 81%; and VeriTrop, 80%) and genotypic (population sequencing/Geno2Pheno with a 10% false-positive rate [FPR], 84%) HIV-1 tropism test results. DeepGen HIV (83%) and Trofile (85%) showed similar concordances with the clinical response following an 8-day course of maraviroc monotherapy (MCT). In summary, this novel all-inclusive HIV-1 genotypic and coreceptor tropism assay, based on deep sequencing of the PR, RT, IN, and V3 regions, permits simultaneous multiplex detection of low-level drug-resistant and/or non-R5 viruses in up to 96 clinical samples. This comprehensive test, the first of its class, will be instrumental in the development of new antiretroviral drugs and, more importantly, will aid in the treatment and management of HIV-infected individuals.

[1]  N. Parkin,et al.  Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants. , 2009, AIDS research and human retroviruses.

[2]  Alexander Thielen,et al.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. , 2011, The Journal of infectious diseases.

[3]  B. Larder,et al.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.

[4]  V. Calvez,et al.  Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.

[5]  Claudia Stewart,et al.  Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA , 2013, Retrovirology.

[6]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[7]  Tobias Sing,et al.  Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.

[8]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[9]  Ram Samudrala,et al.  Antivirogram or Phenosense: A Comparison of their Reproducibility and an Analysis of their Correlation , 2003, Antiviral therapy.

[10]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[11]  E. Poveda,et al.  High Concordance between the Position-Specific Scoring Matrix and Geno2pheno Algorithms for Genotypic Interpretation of HIV-1 Tropism: V3 Length as the Major Cause of Disagreement , 2011, Journal of Clinical Microbiology.

[12]  Brendan Larder,et al.  A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs , 1998, Antimicrobial Agents and Chemotherapy.

[13]  R. Paredes,et al.  Added Value of Deep Sequencing Relative to Population Sequencing in Heavily Pre-Treated HIV-1-Infected Subjects , 2011, PloS one.

[14]  Andrew J. Low,et al.  Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA , 2010, Journal of acquired immune deficiency syndromes.

[15]  D. Kuritzkes,et al.  Clinical implications of HIV-1 minority variants. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Michal Sharon,et al.  Molecular switch for alternative conformations of the HIV-1 V3 region: Implications for phenotype conversion , 2006, Proceedings of the National Academy of Sciences.

[17]  Christos J. Petropoulos,et al.  A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1 , 2000, Antimicrobial Agents and Chemotherapy.

[18]  James H. Bullard,et al.  The origin of the Haitian cholera outbreak strain. , 2011, The New England journal of medicine.

[19]  Gregory S Turenchalk,et al.  Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.

[20]  P. Cliften,et al.  Targeted Exome Sequencing Integrated with Clinicopathological Information Reveals Novel and Rare Mutations in Atypical, Suspected and Unknown Cases of Alport Syndrome or Proteinuria , 2013, PloS one.

[21]  Edward P Acosta,et al.  Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. , 2008, The Journal of infectious diseases.

[22]  T. Dallman,et al.  Performance comparison of benchtop high-throughput sequencing platforms , 2012, Nature Biotechnology.

[23]  R. MacArthur.  Understanding HIV phenotypic resistance testing: usefulness in managing treatment-experienced patients. , 2009, AIDS reviews.

[24]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[25]  D. Robertson,et al.  Sensitive Cell-Based Assay for Determination of Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2013, Journal of Clinical Microbiology.

[26]  Jan Albert,et al.  PCR-Induced Transitions Are the Major Source of Error in Cleaned Ultra-Deep Pyrosequencing Data , 2013, PloS one.

[27]  P Rossi,et al.  Analysis of heterogeneous viral populations by direct DNA sequencing. , 1993, BioTechniques.

[28]  A. Zolopa.  The evolution of HIV treatment guidelines: current state-of-the-art of ART. , 2010, Antiviral research.

[29]  Matthew S. Lalonde,et al.  Sensitive Oligonucleotide Ligation Assay for Low-Level Detection of Nevirapine Resistance Mutations in Human Immunodeficiency Virus Type 1 Quasispecies , 2007, Journal of Clinical Microbiology.

[30]  P. Massip,et al.  Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing , 2011, AIDS.

[31]  Z. Bentwich,et al.  Evaluation of a Benchtop HIV Ultradeep Pyrosequencing Drug Resistance Assay in the Clinical Laboratory , 2013, Journal of Clinical Microbiology.

[32]  B. Clotet,et al.  Prevalence of CCR5-tropic HIV-1 Among Treatment-Experienced Individuals in Spain , 2009, HIV clinical trials.

[33]  Niko Beerenwinkel,et al.  Read length versus Depth of Coverage for Viral Quasispecies Reconstruction , 2012, PloS one.

[34]  E. Poveda,et al.  Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. , 2009, The Journal of antimicrobial chemotherapy.

[35]  P. Harrigan,et al.  Comparison of population and 454 "deep" sequence analysis for HIV type 1 tropism versus the original trofile assay in non-B subtypes. , 2013, AIDS research and human retroviruses.

[36]  Huldrych F. Günthard,et al.  Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection , 2012, PLoS pathogens.

[37]  E. Poveda,et al.  Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters , 2008, Journal of Acquired Immune Deficiency Syndromes.

[38]  M. Nei,et al.  MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. , 2011, Molecular biology and evolution.

[39]  Matthias Cavassini,et al.  Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  W. Heneine,et al.  Comparative Analysis of Two Commercial Phenotypic Assays for Drug Susceptibility Testing of Human Immunodeficiency Virus Type 1 , 2002, Journal of Clinical Microbiology.

[41]  Sergei L. Kosakovsky Pond,et al.  Deep Sequencing Reveals Minor Protease Resistance Mutations in Patients Failing a Protease Inhibitor Regimen , 2012, Journal of Virology.

[42]  Lee T. Sam,et al.  Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.

[43]  Huldrych F Günthard,et al.  2011 update of the drug resistance mutations in HIV-1. , 2011, Topics in antiviral medicine.

[44]  David L. Robertson,et al.  Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II , 2012, BMC Bioinformatics.

[45]  Rodrigo Lopez,et al.  Clustal W and Clustal X version 2.0 , 2007, Bioinform..

[46]  A. Zolopa,et al.  The use of resistance testing in the management of HIV-1-infected patients , 2009, Current opinion in HIV and AIDS.

[47]  S. Hammer,et al.  Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients. , 2010, The Journal of infectious diseases.

[48]  Torsten Seemann,et al.  Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR , 2011, PLoS pathogens.

[49]  M. Kozal,et al.  Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure , 2012, AIDS.

[50]  P. Cane,et al.  Genotypic resistance testing in routine clinical care , 2011, Current opinion in HIV and AIDS.

[51]  M. Quiñones-Mateu,et al.  Current tests to evaluate HIV-1 coreceptor tropism , 2009, Current opinion in HIV and AIDS.

[52]  R. Paredes,et al.  HIV-1 Tropism Testing in Subjects Achieving Undetectable HIV-1 RNA: Diagnostic Accuracy, Viral Evolution and Compartmentalization , 2013, PloS one.

[53]  F. Ceccherini‐Silberstein,et al.  Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. , 2012, The Journal of infectious diseases.

[54]  J. Archer,et al.  Use of Four Next-Generation Sequencing Platforms to Determine HIV-1 Coreceptor Tropism , 2012, PloS one.

[55]  Albert J. Vilella,et al.  Insights into hominid evolution from the gorilla genome sequence , 2012, Nature.

[56]  J. Eshleman,et al.  Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. , 2006, The Journal of molecular diagnostics : JMD.

[57]  E. Ruiz-Mateos,et al.  HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients , 2012, Antimicrobial Agents and Chemotherapy.

[58]  P. André,et al.  Discordance in HIV‐1 Co‐receptor use prediction by different genotypic algorithms and phenotype assay: Intermediate profile in relation to concordant predictions , 2012, Journal of medical virology.

[59]  D. Winner,et al.  Resistance Mutations outside the Integrase Coding Region Have an Effect on Human Immunodeficiency Virus Replicative Fitness but Do Not Affect Its Susceptibility to Integrase Strand Transfer Inhibitors , 2013, PloS one.

[60]  Richard L. Hodinka,et al.  Switching between raltegravir resistance pathways analyzed by deep sequencing , 2011, AIDS.

[61]  R. Paredes,et al.  Genotypic determination of HIV tropism - clinical and methodological recommendations to guide the therapeutic use of CCR5 antagonists. , 2010, AIDS reviews.

[62]  Gundo Weiler,et al.  Global Update on HIV Treatment 2013: Results, Impact and Opportunities , 2013 .

[63]  M. KaganRon,et al.  Comparison of Genotypic and Phenotypic HIV Type 1 Tropism Assay: Results from the Screening Samples of Cenicriviroc Study 202, a Randomized Phase II Trial in Treatment-Naive Subjects , 2014 .

[64]  G. Lucero,et al.  Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion. , 2004, Virology.

[65]  Michael Monsour,et al.  Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.

[66]  Giovanni Chillemi,et al.  Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations , 2009, Retrovirology.

[67]  K. Metzner,et al.  Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. , 2013, The Journal of infectious diseases.

[68]  C. Charpentier,et al.  Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study , 2010, Antimicrobial Agents and Chemotherapy.

[69]  H. Vahaboğlu,et al.  Activities of cefepime and five other antibiotics against nosocomial PER-1-type and/or OXA-10-type beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter spp. , 1998, The Journal of antimicrobial chemotherapy.

[70]  C. Petropoulos,et al.  Comparison of genotyping and phenotyping methods for determining susceptibility of HIV-1 to antiretroviral drugs , 2001, AIDS.

[71]  E. Domingo,et al.  Nucleotide diversity in three different genomic regions of Venezuelan HIV type 1 isolates: a subtyping update. , 1999, AIDS research and human retroviruses.

[72]  E. Arts,et al.  Novel Method for Simultaneous Quantification of Phenotypic Resistance to Maturation, Protease, Reverse Transcriptase, and Integrase HIV Inhibitors Based on 3′Gag(p2/p7/p1/p6)/PR/RT/INT-Recombinant Viruses: a Useful Tool in the Multitarget Era of Antiretroviral Therapy , 2011, Antimicrobial Agents and Chemotherapy.

[73]  J. Izopet,et al.  Phenotyping methods for determining HIV tropism and applications in clinical settings , 2012, Current opinion in HIV and AIDS.

[74]  N. Takahashi,et al.  Nested PCR for detection of mutans streptococci in dental plaque , 2003, Letters in applied microbiology.

[75]  J. Epstein,et al.  Bats are a major natural reservoir for hepaciviruses and pegiviruses , 2013, Proceedings of the National Academy of Sciences.

[76]  Susan M. Huse,et al.  Accuracy and quality of massively parallel DNA pyrosequencing , 2007, Genome Biology.

[77]  P. Harrigan,et al.  Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies , 2010, AIDS.

[78]  R. Paredes,et al.  Next-generation sequencing to assess HIV tropism , 2012, Current opinion in HIV and AIDS.

[79]  A. Wensing,et al.  Transmission of HIV-1 Drug Resistance , 2015 .

[80]  E. Ruiz-Mateos,et al.  Effect of Maraviroc on HIV Disease Progression-Related Biomarkers , 2012, Antimicrobial Agents and Chemotherapy.

[81]  S. Zolla-Pazner,et al.  Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. , 2007, AIDS research and human retroviruses.

[82]  V. Johnson,et al.  Accuracy of the TRUGENE HIV-1 Genotyping Kit , 2003, Journal of Clinical Microbiology.

[83]  L. Bacheler,et al.  Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. , 2007, Journal of virological methods.

[84]  R. Shafer,et al.  Update of the drug resistance mutations in HIV-1: March 2013. , 2013, Topics in antiviral medicine.

[85]  L. Cuzin,et al.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism , 2008, AIDS.

[86]  D. Pillay,et al.  Transmission of HIV-1 drug resistance. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[87]  E. Bunnik,et al.  Detection of Inferred CCR5- and CXCR4-Using HIV-1 Variants and Evolutionary Intermediates Using Ultra-Deep Pyrosequencing , 2011, PLoS pathogens.

[88]  Lior Pachter,et al.  Development of a Low Bias Method for Characterizing Viral Populations Using Next Generation Sequencing Technology , 2010, PloS one.

[89]  Andrew J. Low,et al.  Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates , 2007, Antiviral therapy.

[90]  Lisa M. Frenkel,et al.  Prevalence and Impact of Minority Variant Drug Resistance Mutations in Primary HIV-1 Infection , 2011, PloS one.

[91]  G. D'offizi,et al.  Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection , 2011, AIDS.

[92]  John Archer,et al.  Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing , 2009, AIDS.

[93]  D. Richman,et al.  Minority variants of drug-resistant HIV. , 2010, The Journal of infectious diseases.

[94]  R. Kaiser,et al.  Genotypic Antiretroviral Resistance Testing for Human Immunodeficiency Virus Type 1 Integrase Inhibitors by Use of the TruGene Sequencing System , 2008, Journal of Clinical Microbiology.

[95]  E. Arts,et al.  Natural Variation in the V3 Crown of Human Immunodeficiency Virus Type 1 Affects Replicative Fitness and Entry Inhibitor Sensitivity , 2007, Journal of Virology.

[96]  David L. Robertson,et al.  The Evolutionary Analysis of Emerging Low Frequency HIV-1 CXCR4 Using Variants through Time—An Ultra-Deep Approach , 2010, PLoS Comput. Biol..

[97]  Glenn Oliveira,et al.  Rapid deep sequencing of patient-derived HIV with ion semiconductor technology. , 2013, Journal of virological methods.

[98]  V. Soriano,et al.  Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience. , 2011, Antiviral research.

[99]  Sarah Palmer,et al.  Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy , 2006, AIDS.

[100]  E. Ruiz-Mateos,et al.  TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches , 2010, Journal of Clinical Microbiology.

[101]  S. Deeks,et al.  Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.

[102]  D. O’Connor,et al.  Low-Cost Ultra-Wide Genotyping Using Roche/454 Pyrosequencing for Surveillance of HIV Drug Resistance , 2012, PloS one.

[103]  Gabriella Scarlatti,et al.  Determination of Coreceptor Usage of Human Immunodeficiency Virus Type 1 from Patient Plasma Samples by Using a Recombinant Phenotypic Assay , 2001, Journal of Virology.

[104]  M. Obermeier,et al.  HIV population genotypic tropism testing and its clinical significance , 2012, Current opinion in HIV and AIDS.

[105]  Helen Piontkivska,et al.  HIV type 1 tropism and inhibitors of viral entry: clinical implications. , 2006, AIDS reviews.

[106]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[107]  R. Paredes,et al.  Clinical management of HIV-1 resistance. , 2010, Antiviral research.

[108]  R. Kagan,et al.  A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients , 2012, PloS one.

[109]  P. Massip,et al.  Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[110]  P. Harrigan,et al.  Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods , 2011, Antimicrobial Agents and Chemotherapy.

[111]  K. Metzner,et al.  Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.

[112]  M. Ronaghi,et al.  Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. , 2007, Genome research.

[113]  Nancy F. Hansen,et al.  Accurate Whole Human Genome Sequencing using Reversible Terminator Chemistry , 2008, Nature.

[114]  E. Poveda,et al.  HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitors , 2006, AIDS.

[115]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[116]  M. Jensen,et al.  Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[117]  Ingrid A. Beck,et al.  Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency , 2006, Journal of Clinical Microbiology.

[118]  V. Soriano,et al.  Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. , 2004, Journal of virological methods.

[119]  Feng Gao,et al.  Analysis of Low-Frequency Mutations Associated with Drug Resistance to Raltegravir before Antiretroviral Treatment , 2010, Antimicrobial Agents and Chemotherapy.

[120]  L. Stuyver,et al.  HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays , 2010, AIDS research and therapy.

[121]  R. Bakeman,et al.  Comkappa: A Windows ’95 program for calculating kappa and related statistics , 1998 .

[122]  P. Harrigan.  Optimization of Clinical Cutoffs for Determining HIV Co-Receptor Use by Population and “Deep” Sequencing Methods , 2009 .

[123]  R. Kagan,et al.  Comparison of genotypic and phenotypic HIV type 1 tropism assay: results from the screening samples of Cenicriviroc Study 202, a randomized phase II trial in treatment-naive subjects. , 2014, AIDS research and human retroviruses.

[124]  D. Kuritzkes,et al.  Tropism testing in the clinical management of HIV-1 infection , 2009, Current opinion in HIV and AIDS.

[125]  Roger Paredes,et al.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. , 2010, The Journal of infectious diseases.

[126]  L. Stuyver,et al.  Ultra-deep sequencing of HIV-1 reverse transcriptase before start of an NNRTI-based regimen in treatment-naive patients. , 2012, Virology.

[127]  H. Koike,et al.  Fine De Novo Sequencing of a Fungal Genome Using only SOLiD Short Read Data: Verification on Aspergillus oryzae RIB40 , 2013, PloS one.

[128]  Astrid Gall,et al.  Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes , 2012, Journal of Clinical Microbiology.

[129]  O. Adams,et al.  Expression plasmids are only useful for the investigation of co-receptor tropism and fusion capacity of short HIV-1 envelope domains. , 2010, Journal of virological methods.

[130]  P. Krogstad,et al.  Performance of the Applied Biosystems ViroSeq Human Immunodeficiency Virus Type 1 (HIV-1) Genotyping System for Sequence-Based Analysis of HIV-1 in Pediatric Plasma Samples , 2001, Journal of Clinical Microbiology.